Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Contraceptives and Serotonergic Brain Signaling
NCT05212389Unknown
- Sponsor
- Rigshospitalet
- Start
- Dec 2021
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial comparing Femicept with Placebo (2 arms). Primary endpoint: Change in neostriatal, neocortical, and hippocampal 5-HT4R brain binding at 3 months. Status: unknown.
02
Drugs
femicept
Beyond the preview
Go deeper on NCT05212389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05212389.